747 related articles for article (PubMed ID: 28239999)
61. Therapeutic Potential of Curcumin in the Treatment of Glioblastoma Multiforme.
Shahcheraghi SH; Zangui M; Lotfi M; Ghayour-Mobarhan M; Ghorbani A; Jaliani HZ; Sadeghnia HR; Sahebkar A
Curr Pharm Des; 2019; 25(3):333-342. PubMed ID: 30864499
[TBL] [Abstract][Full Text] [Related]
62. Glioblastoma multiforme: a review of therapeutic targets.
Kanu OO; Mehta A; Di C; Lin N; Bortoff K; Bigner DD; Yan H; Adamson DC
Expert Opin Ther Targets; 2009 Jun; 13(6):701-18. PubMed ID: 19409033
[TBL] [Abstract][Full Text] [Related]
63. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
64. Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme: A Retrospective Multi-Institutional Experience.
Lovo EE; Moreira A; Barahona KC; Ramirez J; Campos F; Tobar C; Caceros V; Sallabanda M; Sallabanda K
Cureus; 2021 Oct; 13(10):e18480. PubMed ID: 34754642
[TBL] [Abstract][Full Text] [Related]
65. Spinal metastasis of glioblastoma multiforme: an uncommon suspect?
Birbilis TA; Matis GK; Eleftheriadis SG; Theodoropoulou EN; Sivridis E
Spine (Phila Pa 1976); 2010 Apr; 35(7):E264-9. PubMed ID: 20195200
[TBL] [Abstract][Full Text] [Related]
66. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
67. Survival Analysis of Glioblastoma Multiforme.
Witthayanuwat S; Pesee M; Supaadirek C; Supakalin N; Thamronganantasakul K; Krusun S
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2613-2617. PubMed ID: 30256068
[TBL] [Abstract][Full Text] [Related]
68. Case presentation - A five-year survival of the patient with glioblastoma brain tumor.
Urbańczyk H; Strączyńska-Niemiec A; Głowacki G; Lange D; Miszczyk L
Rep Pract Oncol Radiother; 2014 Sep; 19(5):347-51. PubMed ID: 25184061
[TBL] [Abstract][Full Text] [Related]
69. Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Feng SW; Wu ZS; Chiu YL; Huang SM
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298208
[TBL] [Abstract][Full Text] [Related]
70. Epidemiology of Anthropometric Factors in Glioblastoma Multiforme-Literature Review.
Simińska D; Korbecki J; Kojder K; Kapczuk P; Fabiańska M; Gutowska I; Machoy-Mokrzyńska A; Chlubek D; Baranowska-Bosiacka I
Brain Sci; 2021 Jan; 11(1):. PubMed ID: 33467126
[TBL] [Abstract][Full Text] [Related]
71. Molecular targeted therapy: A new avenue in glioblastoma treatment.
El Atat O; Naser R; Abdelkhalek M; Habib RA; El Sibai M
Oncol Lett; 2023 Feb; 25(2):46. PubMed ID: 36644133
[TBL] [Abstract][Full Text] [Related]
72. Intranasal delivery in glioblastoma treatment: prospective molecular treatment modalities.
Morales DE; Mousa S
Heliyon; 2022 May; 8(5):e09517. PubMed ID: 35647354
[TBL] [Abstract][Full Text] [Related]
73. Engineering Nanomedicine for Non-Viral RNA-Based Gene Therapy of Glioblastoma.
He W; Wang N; Wang Y; Liu M; Qing Q; Su Q; Zou Y; Liu Y
Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675144
[TBL] [Abstract][Full Text] [Related]
74. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
75. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
76. Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme.
Mishra VS; Kumar N; Raza M; Sehrawat S
Oncotarget; 2020 Dec; 11(51):4754-4769. PubMed ID: 33473259
[TBL] [Abstract][Full Text] [Related]
77. Extra central nervous system metastases from cerebral glioblastoma multiforme in elderly patients. Clinico-pathological remarks on our series of seven cases and critical review of the literature.
Piccirilli M; Brunetto GM; Rocchi G; Giangaspero F; Salvati M
Tumori; 2008; 94(1):40-51. PubMed ID: 18468334
[TBL] [Abstract][Full Text] [Related]
78. Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas.
St-Coeur PD; Touaibia M; Cuperlovic-Culf M; Morin P
Genomics Proteomics Bioinformatics; 2013 Aug; 11(4):199-206. PubMed ID: 23732626
[TBL] [Abstract][Full Text] [Related]
79. Variegated Colors of Pediatric Glioblastoma Multiforme: What to Expect?
Immanuel V; Kingsley PA; Negi P; Isaacs R; Grewal SS
Rare Tumors; 2017 Jul; 9(2):6552. PubMed ID: 28975017
[TBL] [Abstract][Full Text] [Related]
80. Blockade of STAT3 Signaling Contributes to Anticancer Effect of 5-Acetyloxy-6,7,8,4'-Tetra-Methoxyflavone, a Tangeretin Derivative, on Human Glioblastoma Multiforme Cells.
Cheng YP; Li S; Chuang WL; Li CH; Chen GJ; Chang CC; Or CR; Lin PY; Chang CC
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31323961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
